Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin

Clinical and Laboratory Haematology

Volumn 21, Issue 1, 1999, Pages 55-60

  Kovacs, M J ^a   Keeney, M ^a   MacKinnon, K ^a   Boyle, E ^a  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Anti Xa levels; Dalteparin; Heparin; Monitoring; Thrombosis

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULANT THERAPY; ARTICLE; CLINICAL ARTICLE; HEMATOLOGICAL PARAMETERS; HUMAN; INTERMETHOD COMPARISON; PATIENT MONITORING; PRIORITY JOURNAL; THROMBOEMBOLISM; THROMBOSIS;

ANALYSIS OF VARIANCE; ANTIBODIES; CHROMOGENIC COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; VENOUS THROMBOSIS;

EID: 0033039419     PISSN: 01419854     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2257.1999.00183.x     Document Type: Article

References (14)

1. Abildgaard U., Norrheim L., Larsen A.E., Nesvold A., Sandset M. & Odegaard R. (1990) Monitoring therapy with LMW heparin: a comparison of three chromogenic substrate assays and the heptest clotting assay. Haemostasis 20, 193-203.
2. Boneu B. (1994) Low molecular weight heparin therapy: is monitoring needed? Thrombosis and Haemostasis 72, 330-334.
3. Brill-Edwards P., Ginsberg J.S., Johnston M. & Hirsh J. (1993) Establishing a therapeutic range for heparin. Annals of Internal Medicine 119, 104-109.
4. Dignanc M., Gabaig A.M., Cambus J.P. & Boneu B. (1993) A new chronometric assay to determine plasma antifactor Xa activity which is insensitive to the antithrombin activity of low molecular weight heparins. Nouvelle Revue Francaise d'Hématologie 35, 545-549.
5. Hardy J.F., Bélisle S., Robitaille D., Perrault J., Roy M. & Gagnon L. (1996) Measurement of heparin concentration in whole blood with the Hepcon/HMS device does not agree with laboratory determination of plasma heparin concentration using a chromogenic substrate for activated factor X. Journal of Thoracic and Cardiovascular Surgery 112, 154-161.
6. Hirsh J. & Poller L. (1994) The International Normalized Ratio: a guide to understanding and correcting its problems. Archives of Internal Medicine 154, 282-288.
7. Hull R.D., Raskob G.E., Hirsh J. et al (1986) Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. New England Journal of Medicine 315, 1109-1114.
8. Kitchen S. & Preston F.E. (1996) Therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays. Thrombosis and Haemostasis 75, 734-739.
9. Kovacs M.J., Keeney M., Weir K. & MacKinnon K. (1996) A comparison of three methods of measuring low molecular weight heparin activity after total knee or hip arthroplasty. Laboratory Hematology 2, 111-114.
10. Levine M., Gent M., Hirsh J. et al. (1996) A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered iin the hospital for proximal deep-vein thrombosis. New England Journal of Medicine 334, 677-681.
11. Mitchell L., Vegh P., Johnston M. & Andrew M. (1996) Standard heparin assays are influenced by endogenous antithrombin (AT) levels. Blood 88, 173a (Abstract).
12. Walenga J.M. (1993) Practical issues on the laboratory monitoring of low molecular weight heparins and related polysaccharides. Semininars in Thrombosis and Hemostasis 19, 69-72.
13. Weinmann E.E. & Salzman E.W. (1994) Deep-vein thrombosis. New England Journal of Medicine 331, 1630-1641.
14. Weitz J.I. (1997) Low-molecular-weight heparins. New England Journal of Medicine 337, 688-698.